Semax: Brain-Signalling Results and Clinical Evidence
AXON Research Institute • AXON Peptide affiliation
Educational draft • Scientific + legal review pending
Silent film with full on-screen captions. Conceptual illustrations, not molecular structures.

Semax research includes experiments on brain signalling. A 2006 study measured BDNF-related changes in the rat hippocampus, a brain region involved in learning and memory. A change in a signalling protein can suggest a mechanism. It does not, by itself, show better memory or a useful treatment effect in people. FDA’s July 2026 briefing found insufficient effectiveness evidence for Semax-related substances in cerebral ischemia, migraine and trigeminal neuralgia. That assessment concerns specific proposed uses. The same briefing raises product-characterization and safety concerns. Keep the exact substance, study population and clinical outcome visible when assessing a claim about Semax.

END CARD
Educational draft. Not medical advice. Sources and limitations accompany this film.

SOURCES
[1] Dolotov et al. (2006): Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus
https://pubmed.ncbi.nlm.nih.gov/16996037/
Primary rat mechanistic study; indexed abstract reviewed

[2] FDA: Semax-related bulk drug substances briefing for July 23-24, 2026 PCAC meeting
https://www.fda.gov/media/193348/download
Official dated regulatory scientific assessment

EVIDENCE LIMITATIONS
Do not convert BDNF findings into a claim of human brain repair or improved intelligence.
The FDA briefing is a dated assessment, not itself a final rule or approval decision.
The briefing distinguishes Semax free base from Semax acetate; do not erase formulation differences.
No current claim is made about authorization in Russia or other jurisdictions.

TOPIC INVENTORY PROVENANCE (not reused audiovisual media)
Original topic requested by Nina; not attributed to an additional verified Facebook video.